Evidence map›Paper›PMID 27102165›Full record

ArticleInternational journal of molecular sciences2016

Ocular Stem Cell Research from Basic Science to Clinical Application: A Report from Zhongshan Ophthalmic Center Ocular Stem Cell Symposium.

Hong Ouyang, Jeffrey L Goldberg, Shuyi Chen, Wei Li, Guo-Tong Xu, Wei Li, Kang Zhang, Robert B Nussenblatt, Yizhi Liu, Ting Xie and 2 more

Open access · goldAbstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 2 countries.

Hong OuyangState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. ouyhong3@mail.sysu.edu.cn.
Jeffrey L GoldbergDepartment of Ophthalmology, Stanford University, Palo Alto, CA 94303, USA. Jeffrey.Goldberg@Stanford.edu.
Shuyi ChenState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. chenshy23@mail.sysu.edu.cn.
Wei LiUnit on Retinal Neurophysiology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. liwei2@nei.nih.gov.
Guo-Tong XuDepartment of Ophthalmology, Tongji University, Shanghai 200092, China. gtxu@tongji.edu.cn.
Wei LiDepartment of Ophthalmology, Xiamen University, Xiamen 361005, China. wei1018@xmu.edu.cn.
Kang ZhangDepartment of Ophthalmology, University of California San Diego, San Diego, CA 92093, USA. k5zhang@ad.ucsd.edu.
Robert B NussenblattLaboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, USA. nussenblattr@nei.nih.gov.
Yizhi LiuState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. yzliu62@yahoo.com.
Ting XieStowers Institute for Medical Research, Kansas City, MO 64110, USA. tgx@stowers.org.
Chi-Chao ChanState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China. chanc@nei.nih.gov.
Donald J ZackWilmer Ophthalmological Institute, Johns Hopkins University, Baltimore, MD 21231, USA. dzack@jhmi.edu.
Sun Yat-sen University · CNNational Eye Institute · USJohns Hopkins Medicine · USStanford University · USStowers Institute for Medical Research · USTongji University · CNUniversity of California, San Diego · USXiamen University · CN

Funding

Dual Leucine Zipper Kinase (DLK) as a Mediator of Retinal Ganglion Cell InjuryR01EY023754 · NEI · JOHNS HOPKINS UNIVERSITY · PI ZACK, DONALD J. · 2013 to 2016
$1.6M
NEI NIH HHS R01 EY023754
6 · The paper itself

Abstract

Stem cells hold promise for treating a wide variety of diseases, including degenerative disorders of the eye. The eye is an ideal organ for stem cell therapy because of its relative immunological privilege, surgical accessibility, and its being a self-contained system. The eye also has many potential target diseases amenable to stem cell-based treatment, such as corneal limbal stem cell deficiency, glaucoma, age-related macular degeneration (AMD), and retinitis pigmentosa (RP). Among them, AMD and glaucoma are the two most common diseases, affecting over 200 million people worldwide. Recent results on the clinical trial of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) in treating dry AMD and Stargardt's disease in the US, Japan, England, and China have generated great excitement and hope. This marks the beginning of the ocular stem cell therapy era. The recent Zhongshan Ophthalmic Center Ocular Stem Cell Symposium discussed the potential applications of various stem cell types in stem cell-based therapies, drug discoveries and tissue engineering for treating ocular diseases.

Indexed as

Stem Cell TransplantationAnimalsEmbryonic Stem CellsHumansInduced Pluripotent Stem CellsRetinal DiseasesRetinal Pigment Epitheliumage-related macular degenerationeye diseasesglaucomalimbal stem cell deficiencyregenerative medicinestem cells

Identifiers

PMID27102165
PMCPMC4813266
OpenAlexW2310282476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.